- Category
- Micro (2024-25)
- Udyam number
- UDYAM-PB-12-0132924

Reckwel Pharma Private Limited
About Reckwel Pharma Private Limited
Data last updated:
Reckwel Pharma Private Limited is a private limited company based in Ludhiana, Punjab, India. It operates in the manufacturing segment of the chemicals sector. It was incorporated on 23 December 2022.
The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN U24200PB2022PTC057522.
The company has an authorised share capital of ₹15 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors Jobanpreet Singh (Whole-Time Director) and Gurjinder Singh Bhullar.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 1425/2 1st Floor Near Sabzi Mandi Haibowal Khurd Ludhiana, Punjab, India – 141001.
As per MCA filings, the company has open charges of ₹98.83 Lakh on record.
Reckwel Pharma Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-PB-12-0132924). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Recognitions & Rankings of Reckwel Pharma
Contact details
Reckwel Pharma Private Limited's registered office is in Ludhiana, Punjab.
- Registered Address1425/2 1st Floor Near Sabzi Mandi Haibowal Khurd Ludhiana, Punjab, India – 141001
- IndustryChemicals, Manufacturing, Other Chemical Product
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Reckwel Pharma Private Limited
FY 2025 filings availableFinancial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | |||
| Other Income | |||
| Total Revenue | |||
| Cost of Materials Consumed | |||
| Employee Benefit Expense | |||
| Finance Costs | |||
| Depreciation and Amortisation | |||
| Other Expenses | |||
| Total Expenses | |||
| EBITDA | |||
| Profit Before Tax | |||
| Tax Expense | |||
| Net Profit (PAT) | |||
| Balance Sheet | |||
| Share Capital | |||
| Reserves and Surplus | |||
| Net Worth (Total Equity) | |||
| Long-term Borrowings | |||
| Short-term Borrowings | |||
| Trade Payables | |||
| Total Liabilities | |||
| Fixed Assets | |||
| Investments | |||
| Inventories | |||
| Trade Receivables | |||
| Cash and Bank Balance | |||
| Total Assets | |||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | |||
| Net Profit Margin | |||
| Return on Equity (ROE) | |||
| Return on Capital Employed (ROCE) | |||
| Return on Assets (ROA) | |||
| Liquidity and Debt | |||
| Current Ratio | |||
| Quick Ratio | |||
| Debt-to-Equity Ratio | |||
| Interest Coverage Ratio | |||
| Efficiency and Growth | |||
| Asset Turnover | |||
| Receivable Days | |||
| Payable Days | |||
| Inventory Days | |||
| Revenue Growth | |||
| Net Profit Growth | |||
To see the full financial statements and ratios of Reckwel Pharma Private Limited, buy the company report.
Board of directors of Reckwel Pharma Private Limited
Reckwel Pharma has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Gurjinder Singh Bhullar | Director | 23 Dec 2022 | 3 Years 10 Months | Current |
| Jobanpreet Singh | Whole-Time Director | 23 Dec 2022 | 3 Years 10 Months | Current |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 25 Feb 2025 | 101062064 | Others | ₹98.83 Lakh | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Reckwel Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Reckwel Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Reckwel Pharma Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Reckwel Pharma Private Limited has 2 board changes on record since 2022: 2 appointments. The latest: Gurjinder Singh Bhullar was appointed as Director on 23 Dec 2022.
Frequently asked questions
Reckwel Pharma is an active private limited company based in Ludhiana, Punjab, India. The company works in manufacturing, within the chemicals industry. It was incorporated on 23 December 2022 (4+ years old) and is registered under CIN U24200PB2022PTC057522.
Reckwel Pharma has 2 current directors:
- Jobanpreet Singh - Whole-Time Director
- Gurjinder Singh Bhullar - Director
The latest financial statements of Reckwel Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2023 are in the company report.
The CIN (Corporate Identification Number) of Reckwel Pharma is U24200PB2022PTC057522. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Reckwel Pharma was incorporated on 23 December 2022, making it 4+ years old. It is registered with the Registrar of Companies, Chandigarh.
Gurjinder Singh Bhullar was appointed as Director on 23 Dec 2022. Jobanpreet Singh was appointed as Whole-Time Director on 23 Dec 2022.
Yes, Reckwel Pharma is registered as a micro enterprise under Udyam registration (number: UDYAM-PB-12-0132924).
The registered office of Reckwel Pharma is at 14252 1st Floor Near Sabzi Mandi Haibowal Khurd Ludhiana, Punjab, India – 141001.
Reckwel Pharma operates in the chemicals industry, in the manufacturing segment.
Reckwel Pharma has open charges of ₹98.83 Lakh and no satisfied charges on record as per latest MCA filings.